Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the GLP-1 Receptor Agonist Market Heading Into 2029?

The market for GLP-1 receptor agonist has been consistently expanding over the past few years. It is expected to rise from $13.58 billion in 2024 to $14.09 billion in 2025, with a compound annual growth rate (CAGR) of 3.8%. The expansion during the historical period can be credited to an increase in diabetes cases, clinical effectiveness, patient awareness and acceptance, global health initiatives, and a preference among patients for injectable treatments.

Expectations suggest the GLP-1 receptor agonist market will experience substantial growth in the coming years, increasing to $17.36 billion by the year 2029 at a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this anticipated growth during the forecast period include increased focus on lifestyle management, the rise of personalized medicine, wider indications, the evolution of next-generation products, and incorporation into combined therapies. The forecast period also sees a shift towards introducing oral formulations, prioritizing combination therapies, building strategic partnerships and collaborations, refining reimbursement policies and accessibility, and adopting patient-focused approaches.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Which Factors Are Pushing The GLP-1 Receptor Agonist Market Forward?

The enhanced prevalence of diabetes is foreseen to boost the GLP-1 receptor agonist market. Diabetes, a persistent disease, emerges when there is insufficient insulin production from the pancreas, or when the body is unable to effectively use the provided insulin. Elevated blood sugar levels are a sign of this metabolic disorder, diabetes mellitus. The GLP-1 receptor agonist is applied in diabetes treatment to encourage the body to generate increased insulin levels, consequently reducing blood sugar levels. Thus, an uptick in diabetes cases will enhance the market growth. For example, the UK’s Office for Health Improvement and Disparities reported in March 2024 that between March 2022 and March 2023, there was a 22% increase in type 1 diabetes patients receiving all eight recommended care processes, while in type 2 diabetes, it rose by 21%. In addition, the percentage of people achieving their HbA1c target levels reached 37.9%, representing the highest value ever documented by the National Diabetes Audit (NDA). As a result, the escalating occurrence of diabetes is fuelling the GLP-1 receptor agonist market.

Which Segment Held The Largest Share In The GLP-1 Receptor Agonist Market In 2025?

The glp-1 receptor agonist market covered in this report is segmented –

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs

2) By Route Of Administration: Parenteral, Oral

3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:

1) By Exenatide: Byetta, Bydureon

2) By Liraglutide: Victoza, Saxenda

3) By Dulaglutide: Trulicity

4) By Lixisenatide: Adlyxin

5) By Other Drugs: Semaglutide, Tirzepatide, Others

How Are Key Trends Driving Expansion In The GLP-1 Receptor Agonist Industry?

In the GLP-1 receptor agonist market, a prominent trend has emerged in the form of product innovations. The major players in this sector are endeavoring to bring forth innovative solutions as a strategy to consolidate their market presence. For instance, in May 2022, Eli Lilly and Company, a pharmaceutical establishment based in the U.S., which is devoted to improving lives through their medicines, introduced their newly FDA-approved product, Mounjaro, a GIP and GLP-1 receptor agonist. This product has been uniquely designed with a single molecule that activates the body’s receptors for the incretin hormones GIP and GLP-1. It is provided as an auto-injector pen with a previously attached, concealed needle, which users are not required to manage or see and is available in 6 different doses.

Which Organizations Are Driving Progress In The GLP-1 Receptor Agonist Industry?

Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Which Region Is Expected To Experience The Highest Growth In The GLP-1 Receptor Agonist Industry?

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model